| Literature DB >> 29056511 |
Subodh Verma1, Lawrence A Leiter2, Deepak L Bhatt3.
Abstract
Despite overwhelming basic science linking inflammation to the pathobiology of atherothrombosis, the specific clinical evidence indicating cardiovascular benefits from anti-inflammatory pharmacotherapy has been lacking. The CANTOS trial (Ridker et al., 2017a) now provides the first largescale proof of concept that inflammasome targeting can reduce cardiovascular events-and, surprisingly, lung cancer.Entities:
Mesh：
Substances：
Year: 2017 PMID： 29056511 DOI： 10.1016/j.cmet.2017.09.022
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287